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OBJECTIVE: To evaluate the resource utilization after
introduction of new treatment guidelines in Asthma
(1997). METHODS: Paid claims for inpatient, outpatient
and pharmacy services during the period 1994 through
2000 were collected. New treatment guidelines solicited
use of anti-inﬂammatory medications for patients using
more than 1 canister of beta-inhaler /month. Chronic
users (CUs): using more than 10 canisters of beta-
inhaler/year. Patients were further categorized: CHBYAi
(CUs, using some anti-inﬂammatory medication; “appro-
priate therapy”) and CHBNAi (CUs not using any anti-
inﬂammatory medication). Univariate analyses for
continuous variables was performed using Wilcoxon-
Rank Sum test and multivariate logistic regression was
performed to predict the probability of being on appro-
priate therapy. RESULTS: A total of 1293 patients were
using more than 10 canisters of beta-inhalers, of which
923 (71%) were on appropriate therapy. The CHBNAi,
for year 1998, had signiﬁcantly fewer asthma-related
physician visits (52.6 Vs 81.0) and costs (59.9 Vs 111.8);
asthma-related hospital visits (78.0 Vs 90.0) and costs
(90.5 Vs 112.3) compared to CHBYAi (p < 0.001); 
statistically signiﬁcant and consistent across the years.
Adjusted r-square for multivariate logistic regression
across the years: 15.1% to 28.9%. Total asthma-related
physician visits and age (1998) were signiﬁcantly associ-
ated with the odds of being on appropriate therapy across
all the years. For example, in 1998, each patient, with
asthma-related physician visit was twice as likely (90%
CI: 1.410–2.843), and each unit increase in age was 0.981
times likely (90% CI: 0.965–0.998); to be on appropri-
ate therapy. CONCLUSION: Per the guidelines, we
would have expected a higher health care utilization
(visits & cost) for the CHBNAi group but we could not
conclude this and it could be related to factors such as
severity of illness.
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OBJECTIVES: The objective of this analysis was to inves-
tigate direct cost of asthma exacerbations in Poland from
the perspective of the payer and the service provider.
METHODS: To examine the current practice of asthma
exacerbations treatment a survey in 4 hospitals was per-
formed. The hospitals were chosen on the basis of differ-
ent ﬁxed cost class. In those hospitals data concerning 
the cost of asthma exacerbations treatment were col-
lected. According to current practice severe asthma exac-
erbations were treated in-patiently and mild or moderate
asthma exacerbations were treated in hospital emergency
rooms (usual stay for one day). The following costs were
calculated for inpatient care (severe exacerbations): hos-
pital stay, pharmaceuticals, personnel, and diagnostic
procedures. An assumption that average hospital admis-
sion took 10 days was made. On the basis of collected
data the pharmaceuticals utilization per 10-day hospital
stay was assessed. For the purpose of this assessment the
decision tree was formulated: the proportions expressing
probabilities of patients receiving speciﬁc drug therapy,
duration of drug therapy and route of the drug adminis-
tration were calculated. For asthma exacerbations treated
in hospital emergency room similar cost groups were
included. Sensitivity analysis was performed. RESULTS:
The average costs per patient care were estimated: hospi-
tal stay 200 PLN (€50) 1 day; drug utilization 435.3 PLN
(€110); 10 day personnel 66.39 PLN (€17); 1 day diag-
nostic procedures 91.4 PLN (€23) per hospital admission.
The average cost of inpatient treated (10 days) asthma
exacerbation was estimated at 3190.61 (€798) per one
patient. The average cost of asthma hospital emergency
room care was estimated at 172.60 PLN (€40) per
patient/day. CONCLUSION: This cost analysis of asthma
exacerbations treatment is one of the ﬁrst performed in
Poland. Further analysis should include more centers to
allow conﬁdence interval estimation.
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OBJECTIVES: To compare “homeopathic drugs” strat-
egy (H) with “antibiotic drugs” strategy (A) for treating
recurrent acute rhinopharyngitis in France, in terms 
of effectiveness, quality of life, and costs. METHODS:
Effectiveness, quality of life, and costs were derived from
a 6-month pragmatic prospective study including 499
“children aged between 18 months and 4 years, who
experienced at least 5 bouts of rhinopharyngitis in 1999,
and who consulted a homeopathic or non-homeopathic
GP for the ﬁrst time in 2000 either for preventive treat-
ment or for a current bout”. Strategy H included 241 chil-
